Journal
VIRUSES-BASEL
Volume 14, Issue 2, Pages -Publisher
MDPI
DOI: 10.3390/v14020187
Keywords
COVID-19; SARS-CoV-2; neutralizing antibody; BNT162b2; mRNA-1273; IgA; IgG; sterilizing immunity; mucosal vaccines; intranasal vaccine; oral vaccines
Categories
Ask authors/readers for more resources
This article discusses the importance of achieving sterilizing immunity through vaccination to prevent the spread of infection from vaccinees, particularly in hospital settings. It also explores the potential implications of sterilizing immunity for animal reservoirs and public health.
Sterilizing immunity after vaccination is desirable to prevent the spread of infection from vaccinees, which can be especially dangerous in hospital settings while managing frail patients. Sterilizing immunity requires neutralizing antibodies at the site of infection, which for respiratory viruses such as SARS-CoV-2 implies the occurrence of neutralizing IgA in mucosal secretions. Systemic vaccination by intramuscular delivery induces no or low-titer neutralizing IgA against vaccine antigens. Mucosal priming or boosting, is needed to provide sterilizing immunity. On the other side of the coin, sterilizing immunity, by zeroing interhuman transmission, could confine SARS-CoV-2 in animal reservoirs, preventing spontaneous attenuation of virulence in humans as presumably happened with the endemic coronaviruses. We review here the pros and cons of each vaccination strategy, the current mucosal SARS-CoV-2 vaccines under development, and their implications for public health.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available